This poll examines the public’s assessments of the Biden administration’s handling of the coronavirus pandemic, the impact COVID-19 has had on people’s finances, and support for provisions of the latest COVID-19 relief bill. It examines the public’s views of the ACA and possible next steps.

This analysis estimates the total annual reduction in health care spending by employers and privately insured individuals that would result from having private insurers reimburse hospitals and other health care providers at Medicare rates. In total, we estimate spending for the privately insured population would be an estimated $352 billion lower in 2021.

This issue brief provides an overview of COVAX, the global mechanism to secure and deliver COVID-19 vaccines. The brief details COVAX’s organization, conditions for country participation, activities, and financing structure. Additionally, it looks at the history and remaining key issues of U.S. engagement with COVAX.

This brief provides a status update on prescription drug final rules advanced by the Trump Administration in its final months related to Medicare, importation, and 340B pricing for insulin and epinephrine, and an overview of key drug pricing proposals related to Medicare and prescription drug prices generally that may return to the forefront of health policy discussions in the coming years.